亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Microbiome Based Treatment for Cirrhosis Patients

詳細技術說明
Cirrhosis is a major cause of death/disability worldwide and the eighth leading cause of death in the US in 2010. Cirrhosis patients have a high likelihood of multiple hospitalizations and developing infections. One major reason is related to dysbiosis or unfavorable microbiome of the gut. Overuse of antibiotics in cirrhosis results in increase of culture-negative and fungal infections from dysbiosis.
*Abstract

From a patient’s microbiome sample screening (16S rRNA bacterial) we can predict which patients:

  • have fungal overgrowth requiring a lower threshold for anti-fungal coverage
  • are unlikely to sustain further antibiotic use
  • are likely to need repletion of their microbiome using:
    • probiotics
    • prebiotics
    • fecal microbial transplant
  • are expected to get re-hospitalized within 90 days
  • to treat with antibiotics or antifungal agents

Clinical Trials: 169 patients, over 90% accuracy identifying/predicting infections
國家/地區
美國

欲了解更多信息，請點擊 這裡
移動設備